GLPwatch

Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.

Eur J Endocrinol · 2019

Last updated 2026-05-28

In a study of 12 people who had gastric bypass surgery, researchers tested whether a GLP-1 drug (exenatide) affected the body’s response to low blood sugar during a controlled experiment. The drug did not change levels of key hormones or the amount of glucose needed to stabilize blood sugar, but it may have reduced the balance between certain nerve activities. No difference in symptoms of low blood sugar was reported between the drug and placebo.

AI summary of the abstract below.

JournalEur J Endocrinol, 2019
Citations19
Relative citation ratio1.08
NIH percentile53
Molecules
Conditions studied Type 2 Diabetes

Abstract

OBJECTIVES: The aim of the study was to explore the role of GLP-1 receptor activation on the counter-regulation and symptoms of hypoglycemia in subjects who have undergone gastric bypass surgery (GBP). DESIGN: Experimental hyperinsulinemic-hypoglycemic clamp study. METHODS: Twelve post-GBP subjects participated in a randomized cross-over study with two hyperinsulinemic, hypoglycemic clamps (glucose nadir 2.7 mmol/L) performed on separate days with concomitant infusions of the GLP-1 analog exenatide or with saline, respectively. Continuous measurements of metabolites and counter-regulatory hormones as well as assessments of heart rate variability and symptoms of hypoglycemia were performed throughout the clamps. RESULTS: No effect of GLP-1 receptor activation on counter-regulatory hormones (glucagon, catecholamines, cortisol, GH) or glucose infusion rate was seen, but we found indications of a downregulation of the sympathetic relative to the parasympathetic nerve activity, as reflected in heart rate variability. No significant differences in symptom of hypoglycemia were observed. CONCLUSIONS/INTERPRETATION: Short-term exposure to a GLP-1 receptor agonist does not seem to impact the counter-regulatory hormonal and metabolic responses in post-GBP subjects during hypoglycemic conditions, suggesting that the improvement in symptomatic hypoglycemia post-GBP seen following treatment with GLP-1 receptor agonists may be mediated by mechanism not directly involved in counter-regulation.

Verbatim abstract via PubMed 31176298 ↗